11:53 AM
 | 
Jul 13, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

Advaxis Inc. (NASDAQ:ADXS) said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001).

The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab to treat advanced, recurrent or refractory cervical cancer and HPV-associated squamous cell carcinoma of...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >